Altre lingue NeuroSense Therapeutics Ltd.

Azioni

NRSN

IL0011809592

Tempo differito Nasdaq Altri mercati azionari 20:05:37 01/05/2024			Variaz. 5gg	Var. 1 gen.
1,31 ^USD	-2,96%		-2,24%	+66,88%

22/04	NeuroSense Therapeutics Ltd. e Genetika+ avviano una collaborazione di medicina di precisione a partire dalla sperimentazione clinica di Fase 2 in corso nella malattia di Alzheimer	CI
18/04	NeuroSense Therapeutics Ltd. presenta dati positivi che convalidano i risultati di fase 2b durante la presentazione Emerging Science all'incontro annuale dell'American Academy of Neurology.	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

NeuroSense to Collaborate With Genetika+ on Alzheimer's Disease Drug Development; Shares Fall	22/04
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease	22/04
NeuroSense Therapeutics Ltd. and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease	22/04
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting	19/04
NeuroSense Therapeutics Ltd. Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting	18/04
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024	15/04
NeuroSense Therapeutics Prices $4.5 Million Offering of Ordinary Shares, Warrants	11/04
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement	11/04
NeuroSense Therapeutics Ltd. announced that it expects to receive $4.47 million in funding	10/04
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics	09/04
NeuroSense Therapeutics Ltd. Collaborates with Lonza to Identify Exosome-Based Biomarkers, in Order to Advance Neurodegenerative Disease Treatments and Diagnostics	09/04
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update	08/04
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update	05/04
NeuroSense Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04/04
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial	21/02
Neurosense Therapeutics Ltd. Reports Additional Positive Results from Its ALS Phase 2B Paradigm Trial	21/02
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule	07/02
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts	09/01
NeuroSense Gets Non-Compliance Notice From Nasdaq	28/12
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement	27/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue NeuroSense Therapeutics Ltd.

Azioni

NRSN

IL0011809592

Altre lingue

Filtri